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Working memorySmoking prevalence in schizophrenia is signiﬁcantly elevated relative to other clinical and to non-clinical groups.
The cognitive self-medication hypothesis attributes this to the beneﬁcial effects of nicotine on illness-related cog-
nitive deﬁcits. Signiﬁcant effects of nicotine have been observed on visual spatial working memory (VSWM),
sustained attention (Continuous Performance Test— Identical Pairs; CPT-IP) and prepulse inhibition (PPI). It re-
mains unclear whether these neurophysiological and neurocognitive effects of nicotine inﬂuence self-reported
smoking motivation.
To explore the relationship between nicotine effects on cognition and self-reported smoking motivation in
schizophrenia and non-psychiatric control smokers, the impact of smoking abstinence and reinstatement was
examined across three cognitive indices (VSWM, CPT-IP, PPI) and compared to self-reported smokingmotivation
(Modiﬁed Reasons for Smoking Scale revised to include ‘cognitive motivators’). Cognitive function was assessed
after ‘typical’ smoking and overnight abstinence. Schizophrenia smokers (but not controls) demonstrated signif-
icantly less error on the VSWM task in the smoking relative to abstinent condition. Control (but not schizophre-
nia) smokers, showed evidence of CPT-IP improvement in the smoking relative to abstinent condition. The
overall proﬁle of smoking motivation was comparable between groups. However, signiﬁcant relationships be-
tween subjective and objective indices of smoking related cognitive change were observed for controls.
Differential effects of nicotine on cognition have been hypothesised to inﬂuence the pattern and persistence of
smoking in schizophrenia. These preliminary ﬁndings indicate that evidence for such effects is apparent even
in small samples— particularly for VSWM. This is the ﬁrst study to show that neurocognitive effects of smoking
may inﬂuence self-reported smoking motivation.
2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Smoking prevalence in schizophrenia is up to ﬁve times higher than
other clinical and non-clinical groups (de Leon and Diaz, 2005). Com-
monalities in the neurobiological substrates of nicotine transmission
and the pathology of schizophrenia have led to the proposal that nico-
tine may be used to ‘self-medicate’ illness related deﬁcits (Kumari and
Postma, 2005). Schizophrenia is characterised by pathological aberra-
tions in the receptor system responsible formediating the effects of nic-
otine (Leonard, 2003). Nicotinic cholinergic receptor (nAChR)
abnormalities, in turn, have been implicated in the pathogenesis of cog-
nitive dysfunction (Martin and Freedman, 2007). Of particular interest
to the current study, accumulating evidence implicates nAChR dysfunc-
tion in the expression of several putative endophenotypic markers of
schizophrenia, including sensory gating, sustained attention and spatial
working memory (Sacco et al., 2004). Conversely, these domains showr Translational Neuroscience &
ersity of Newcastle, Callaghan,
690; fax: +61 66 02 40335692.
ck).
his is an open access article under th“strong evidence” for nicotinic modulation in schizophrenia (see
Table 3, Sacco et al., 2004). Speciﬁcally, nicotine has been found to tran-
siently ameliorate deﬁcits in auditory sensory gating (Adler et al., 1993;
George et al., 2006), sustained attention (Dépatie et al., 2002; Sacco
et al., 2005) and visual spatial working memory (VSWM; Sacco et al.,
2005). Evidence for facilitatory effects of nicotine in non-smokers with
schizophrenia (Barr et al., 2008) and clinically unaffected relatives
(Adler et al., 1992) indicates that these ﬁndings are largely independent
of withdrawal (and other potential confounds, including chronic expo-
sure to nicotine and psychotropic agents; Adler et al.,1992). However,
there is a paucity of research directly assessing self-reported smoking
motivation in schizophrenia (Forchuk et al., 2002; Gurpegui et al.,
2007; Barr et al., 2008; Galazyn et al., 2010) and potential cognitivemo-
tivators have been largely neglected. Therefore, the degree to which
these cognitive effects subjectively motivate smoking remains unclear.
The aims of the current study were three-fold. Firstly, we assessed
self-reported smokingmotivators, in particular, the perceived importance
of cognitive motivators amongst outpatient smokers with schizophrenia
and a non-psychiatric comparison group. Secondly, we evaluated thee CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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measuring putative endophenotypicmarkers of schizophrenia (sustained
attention, visual spatial workingmemory and sensory gating). Finally, we
explored the relationship between self-reportedmotivations for smoking
(i.e. perceived function of smoking) and objective indices of the physio-
logical impact of nicotine on cognitive functioning.
1. Method
This study consisted of two experimental sessions. A ‘self-report
only’ component was also introduced to assess smoking motivation
amongst individuals unable or unwilling to participate in experimental
sessions. This study was conducted in accordance with the ethical stan-
dards (3.10, 8.01, 8.02 and 8.06) of the American Psychological Associa-
tion. Written, informed consent was obtained from all participants.
Studyprotocolwas approved by theUniversity of Newcastle andHunter
New England Human Research Ethics Committees.
1.1. Participants
Twenty-eight smokers (≥15 cigarettes per day), 16 outpatientswho
met DSM-IV criteria (DIP; Castle et al., 2006) for schizophrenia (n=10)
or schizoaffective disorder (n=6) and 12 community controls without
a personal history of psychosis/major affective disorders (DIP; Castle
et al., 2006) participated in experimental sessions. Exclusion criteria in-
cluded neurological condition (e.g. stroke, epilepsy), signiﬁcant head in-
jury/trauma and evidence of alcohol or illicit substance dependence
within the last six months. An additional 71 smokers, 43 outpatients
with schizophrenia/schizoaffective disorder and 28 non-psychiatric
controls provided self-report data only.
1.2. General procedures
Experimental participants attended two morning appointments (ap-
proximately one week apart), one after abstaining from nicotine from at
least 11 pm (e.g. Adler et al.1993; ‘abstinent’), the other in the context of
usual smoking behaviour (‘smoking’). The order of cognitive assessment
was randomly allocated from one of six testing orders, generated using a
Latin squaredesign. Appointment order (abstinentﬁrst vs. second)was al-
ternated within each of the six testing orders. Self-reported smoking mo-
tivation was assessed during the ‘smoking’ appointment. Self-report only
participants completed a questionnaire pack assessing demographics,
smoking history, self-reported dependence and smoking motivation.
1.3. Measures and instruments
1.3.1. Cigarette and substance use measures
Self-reported smoking status (abstinent vs. smoking) was veriﬁed at
the beginning of experimental appointments with single breath, ex-
pired CO using a Bedfont Micro Smokerlyzer (Air-met Scientiﬁc). For
the abstinent session a CO reading of ≤12 ppm (e.g. Kumari and Gray,
1999) was required. Withdrawal symptoms were assessed using the
Wisconsin Smoking Withdrawal Scale (WSWS; Welsch et al., 1999).
Self-reported nicotine dependence was assessed using the Fagerström
Test for Nicotine Dependence (FTND; Steinberg et al., 2005).
1.4. Smoking motivation
Self-reported smoking motivation was assessed using a revised ver-
sion of the Modiﬁed Reasons for Smoking Scale (MRSS; Tate et al.,
1994). Thirteen items from the Situation × Trait Adaptive Response
Smoking Motivation Questionnaire (STAR-SMQ; Gilbert et al., 2000)
were combined with the MRRS into a single, comprehensive measure
of self-reported smoking motivations (MRRS-Revised). Participants
were required to rate each item using a ﬁve-point Likert scale (1 =
Never, 5 = Always; Forchuk et al., 2002).1.5. Cognitive assessment
1.5.1. VSWM
VSWM was assessed using a computerized task designed in accor-
dance with published speciﬁcations (George et al., 2006). Participants
moved a cursor to the location of a previously observed dot with perfor-
mance indexed by the average distance (error, in cm) between the cur-
sor and the actual location of target presentation, averaged across 16
trials. Higher scores indicate poorer performance.
1.5.2. Sustained attention
Sustained attentionwas assessed using the Continuous Performance
Task — Identical Pairs version (CPT-IP: number trial only; Michie et al.,
2000). Outcome measures included hits (correct responses to targets),
false alarms (catch and ﬁller trials), response time (ms) and discrimina-
tion [dL; Cornblatt et al., 1988], calculated for blocks 1 & 2 of the task
separately to provide sensitivity to changes over the testing period.
1.5.3. PPI
The PPI paradigm was programmed according to published speciﬁ-
cations (George et al., 2006). Auditory stimuli were presented binaural-
ly over headphones. Acoustic startle response was measured via eye-
blinks using electromyographic activity (EMG) collected using Scan
4.3 (Neuroscan Inc, Biomedics). EMG activity was acquired continuous-
ly (A/D rate of 250Hz) and ﬁlteredwith a 0.1–30 Hz bandpass ﬁlter and
5-Hz notch ﬁlter. EMG data were inspected to determine responsive-
ness of participants to the startle alone stimuli. Participants were classi-
ﬁed as ‘acoustic startlers’ if they demonstrated a mean startle response
of ≥ 25 μV in the smoking session (George et al., 2006), with this crite-
rion applied to the mean of the startle alone trial across the ﬁrst three
blocks only (where habituation effects are weakest; Braff et al., 1992)
resulting in the rejection of one schizophrenia participant.
Spontaneous and voluntary eye blinks in these data sets were then
excluded according to previously published criteria (Braff et al., 1992),
with 12.5% of trials in controls and 13.89% of trials in schizophrenia par-
ticipants discarded (comparable to George et al., 2006). Peak amplitude,
peak latency and mean amplitude (over 50–200 ms) values were ex-
tracted for analysis. PPI was deﬁned as the difference in startle magni-
tude (as a percentage) between pulse trials preceded by a prepulse
and pulse alone trials [1−(pp/p)×100; where pp represents the mean
amplitude to pulse trials preceded by a prepulse, and represents the
mean amplitude over pulse alone trials].
2. Results
Statistical analysis was performed using SPSS v 16.0. An alpha level
of .05 was used for all statistical tests.
2.1. Demographic and clinical characteristics
Tables 1 and 2 display results of independent samples t-tests or X2
analyses comparing schizophrenia versus control participants on demo-
graphic, clinical and smoking variables. Schizophrenia participants
demonstrated lower estimated full scale IQ (although within average
limits; Table 1) and higher self-reported nicotine dependence (Table 2).
2.2. Cognitive assessment
Due to small group numbers analysis of all cognitive data was re-
stricted to within-subjects comparisons.
2.2.1. VSWM
Paired-samples t-tests demonstrated that schizophrenia [t(15) =
2.93, p= .01, Cohen’s d= 0.6], but not control (p= .81) smokers dem-
onstrated signiﬁcantly better performance during typical smoking, rela-
tive to short-term (i.e. overnight) abstinence (Fig. 1).
Table 1
Demographic and clinical characteristics for experimental (EXP) and self-report participants (S-R)a.
Schizophrenia Smokers Control Smokers p-value
EXP
(n = 16)
S-R
(n = 43)
EXP
(n = 12)
S-R
(n = 28)
Recruitment Source
CTNMH Volunteer Database 50% 63% – – NA
ASRB Volunteer Database 19% 22% – – NA
HMRI Volunteer Database – – 25% – NA
Media 19% – 25% 7% NA
Flyers 12% 9% 50% 93% NA
Schizophrenia Fellowship – 6% – – NA
Ageb 43 (10.8) 43 (9.78) 37.6 (11.9) 37.68 (8.77) .025⁎
Gender (% Male) 56.3 48.8 50.0 35.7 b .001
WTAR Estimated Full-Scale IQb 99.1 (7.2) 104.3 (5.7) .05⁎
Self-reported age of illness onsetb 21.87 (6.09) 19.08 (4.22) NA NA .11
Duration 21.13 (9.19) 24.97 (9.67) NA NA .19
Antipsychotic classc NA NA –
Atypical 12 35 NA NA
Typical 2 9 NA NA
CPZ equivalents (mg/day)b 363.62 (293.66) 612.05 (466.98) NA NA .03⁎
Note. ASRB = Australian Schizophrenia Research Bank; CTNMH = Centre for Translational Neuroscience andMental Health Research; CPZ = chlorpromazine; HMRI = HunterMedica-
tion Research Institute; WTAR = Weschler Test of Adult Reading.
a Values are expressed as a percentage of the group unless otherwise speciﬁed.
b Values are expressed as mean (SD).
c Values are expressed as the total number of participants.
⁎ Signiﬁcant at p b .05.
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Trial block (one vs. two) and smoke status (abstinent vs. smoking)
were entered into RMANOVA’s performed on each of the CPT-IP perfor-
mance indices. False alarms to ﬁller trials, catch trials and response time
measures were unaffected by smoke status in both groups (all p’s N .17;
data not presented).
The proportion of hits, proportion of false alarms and discrimination
ability (as a function of smoke status and block) appear in Fig. 2. An
RMANOVA performed on control hits conﬁrmed an interaction between
smoke status and block, reﬂecting decline in performance over blocks
[F(1,11) = 11.99, p= .005]. The main effect of smoke status F(1,11) =
15.82, p = .002], but not block (p = .15) reached signiﬁcance. PairedTable 2
Smoking variables for experimental and self-report participantsa.
Schizophrenia Smokers
EXP
(n = 16)
S-R
(n = 43)
Smoking onset (1st full cigarette) 12.9 (4.7) 13.6 (3.8)
Age of daily smoking onset 16.6 (5.3) 17 (4.5)
Years since onset of daily smoking 26.4 (10.2) 25.9 (10.5)
Smoking behaviour in last 12 monthsb
Abstinent (≥1 month) 12.5 17.9
Changed to lower nicotine cigarette 18.8 22.1
Reduced average daily cigarettes 31.3 48.7
Smoking behaviour unchanged 25 25
Lifetime number of quit attempts 5.8 (6.8) 8.9 (13.6)
Longest period of abstinence (weeks)b
b1 12.5 25
1–4 25 20.8
4–28 37.5 31.3
29–52 25 13.5
N52 0 9.4
FTND Total Score 6.8 (1.8) 7.2 (1.7)
FTND Dependence Categoryb
Mild 25 17.6
High 43.8 41.2
Very High 31.3 41.2
Duration (min) between cigarettes 60.94 (55.92)
Range = 10–210
36.89 (22.36)
Range = 5–90
Note. FTND = Fagerström Test for Nicotine Dependence (self-report inventory).
a Values are expressed as mean (SD) unless otherwise speciﬁed.
b Values are expressed as a percentage of the group.
⁎ Signiﬁcant at p b .05.
⁎⁎ Signiﬁcant at p b .01.samples t-tests conﬁrmed that the proportion of hits signiﬁcantly
declined between blocks one and two in the abstinent [t(11) = 2.80,
p = .017; Cohen’s d = 0.86] but not smoking appointment (p= .19).
Conversely, schizophrenia hits appear relatively stable across blocks,
irrespective of appointment (conﬁrmed by RMANOVA all p’s N .36).
In controls, RMANOVA yielded a signiﬁcant smoke status × block
interaction [F(1,11) = 7.89, p= .017] and main effect of smoke status
[F(1,11)=4.82, p= .050]. Discrimination ability signiﬁcantly improved
across blocks in the smoking [paired t(11) =−2.69, p= .021; Cohen’s
d = 0.8], but not abstinent appointments (p= .27), with sensitivity in
block two of ‘smoking’ signiﬁcantly higher than block two of ‘abstinent’
[t(11) = −3.37, p = .006; Cohen’s d = 1.09]. Conversely, theControl Smokers p-value
EXP
(n = 12)
S-R
(n = 28)
14.2 (2.3) 13.6 (3.2) .77
16.1 (2.9) 16.9 (3.9) .53
21.5 (13.3) 20.8 (9.4) .13
41.7 14.3 .18
16.7 28.6 .79
8.3 53.6 .04*
25 32.1 .92
4 (2) 3.8 (4.9) .24
.09
0 27.5
25 22.5
58.3 25
0 17.5
16.7 7.5
5.3 (1.6) 5.8 (2.1) .003⁎⁎
.005⁎⁎
50 65
50 20
0 15
54.79 (19.3)
Range = 30–90
66.66 (49.02) Range = 15–240 .017⁎
Fig. 1. VSWM error demonstrated by schizophrenia and control smokers as a function of
smoking status. ** p = .01.
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improve between blocks one and two, irrespective of smoking status.
However, RMANOVA’s performed on the dL data of schizophrenia par-
ticipants did not reach signiﬁcance (all p’s N .08).Fig. 2. Proportion of hits, proportion of false alarms and discrimination ability (DL) demon
b .05. ** p = b .01.2.2.3. PPI
PPI across the three prepulse intervals (as a function of smoke sta-
tus) appears in Fig. 3. RMANOVA’s revealed no signiﬁcant effect of
smoke status for either group (all p’s N .19). A signiﬁcant effect of trial
type was detected for control [ε = 0.71, F(2,20) = 19.48, p b .001],
but not schizophrenia participants. In controls, PPI was signiﬁcantly
larger in the 60 ms [t(10) = 5.64, p b .001; Cohen’s d = 1.00] and
120 ms [t(10) = 7.65, p b .001; Cohen’s d = 1.09] conditions relative
to the 30 ms condition (no difference was detected between the
60 ms and 120 ms conditions,p= .54).2.3. MRSS-R
Ninety-eight participants (schizophrenia = 58, control = 40)
returned the MRSS-R (one from the schizophrenia group was excluded
due to excessive missing data). MeanMRSS-R subscale scores were en-
tered into a 2 (Group: schizophrenia vs. control) × 8 (Motive: cognitive
vs. automatic vs. addictive vs. stimulation vs. sedative vs. social vs. in-
dulgent vs. sensorimotor manipulation) RMANOVA, with group as a
between-subjects factor and motive as a within-subjects factor. Sepa-
rate ANCOVA’s and Spearman Rank correlations were conducted to de-
termine whether self-reported nicotine dependence (as indexed by
FTND scores) inﬂuenced self-reported motivation to smoke.
Cognitive motives represent an ‘occasional’ reason for smoking in
both groups (Fig. 4a). An RMANOVA conducted on theMRSS-R data pro-
duced a signiﬁcant main effect of motive [ε= .83; F(7,672) = 71.09,
p b .001] but no motive × group interaction (p = .26) or main effect
of group (p= .11).strated by schizophrenia and control smokers as a function of smoking status. * p =
Fig. 3.Mean percentage prepulse inhibition across trial type for control (A) and schizophrenia (B) smokers as a function of smoke status.
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smoking in both groups after co-varying for the effect of FTND
(Fig. 4b). FTND was a signiﬁcant co-variate [F(1,95) = 23.94, p b .001].
Entering FTND as a covariate in an RMANCOVA produced a signiﬁcant
main effect ofmotive [ε=.85; F(7,665)=5.8, p b .001] alongwith a sig-
niﬁcant motive × group interaction [ε= .85; F(7,665) = 2.8, p= .01],
with stronger endorsement of sedative motivators amongst controls
[t(96) = 3.11, p b .01]. The main effect of group remained non-
signiﬁcant (p= .67). Correlations between FTND and MRSS-R subscale
scores are presented at the end of this section in Table 3.2.4. Relationship between cognitive function and self-reported
smoking motivation
Difference scores were calculated for each of the primary cognitive
performance indices (Smoking minus Abstinent). Analyses were con-
ducted separately for each group. Signiﬁcant correlationswere detected
between self-reported cognitive smoking motivation and CPT-IP mea-
sures only and in controls only.
Amongst controls, there was a signiﬁcant positive correlation be-
tween block two hits and the ‘cognitive’ (r = .67, p = .02) motivator
(Fig. 5). That is, stronger endorsement of ‘cognitive’ items was associat-
ed with a larger smoking-related increase in block two hit rate.Fig. 4.MeanMRSS-R subscale scores as a function of clinical group for original (A) and FTND co
inventory). Responseswere scored according to the following scale: 1=Never, 2= Seldom, 3
uated at the following values: FTND = 6.4490.3. Discussion
To our knowledge, this is the ﬁrst study to attempt a multi-level
evaluation of subjective and objective cognitive effects of nicotine. Def-
icits within the three cognitive domains assessed are suspected
endophenotypicmarkers for schizophrenia, and as such, are particularly
pertinent to understanding the relationship between nicotine and cog-
nition within this illness. Consistent with prior research (Sacco et al.,
2005; Smith et al., 2006), smoking vs abstinence had a clear and signif-
icant impact on the VSWM function of smokerswith schizophrenia. Rel-
ative to overnight abstinence, VSWM performance in the smoking
appointment was characterised by signiﬁcantly smaller error. In con-
trast, the VSWM performance of control smokers remained consistent
across appointments. This study provides further support for the sensi-
tivity of VSWM (dys)function to manipulation of nicotine use in
smokers with schizophrenia.
Despite apparent impairments in CPT-IP performance, contrary to
prediction, sustained attention in schizophrenia smokers was unaffect-
ed by the smoking/abstinence manipulation. Conversely, amongst con-
trols, both hits and discrimination ability were signiﬁcantly higher in
the smoking relative to abstinent appointment. The absence of smoking
related change in our schizophrenia group is inconsistent with existing
evidence (Dépatie et al., 2002; Levin et al., 1996; Sacco et al., 2005;
Smith et al., 2006). A notable difference between our study and Dépatievariatea (B) analysis. Note. FTND= Fagerström Test for Nicotine Dependence (self-report
= Occasionally, 4= Frequently, 5 = Always. aCovariates appearing in themodel are eval-
Table 3
Non-parametric correlations between self reported nicotine dependence (FTND) and
MRSS-R subscale scores for schizophrenia and control smokers.
Schizophrenia Control
Factor r p-value r p-value
Cognitive .230 .082 .325 .041⁎
Automatic .216 .103 .499 .001⁎⁎
Addictive .397 .0028 .549 b .001⁎⁎
Stimulation .336 .010⁎ .309 .052
Sedative .384 .003⁎⁎ .477 .002⁎⁎
Social .451 b .001⁎⁎ .122 .455
Indulgent .171 .200 − .084 .607
Sensorimotor Manipulation .171 .198 − .037 .822
⁎ Signiﬁcant at p b .05.
⁎⁎ Signiﬁcant at p b .01.
31A.K. Beck et al. / Schizophrenia Research: Cognition 2 (2015) 26–32et al. (2002) is the route of nicotine administration (smoking vs. trans-
dermal nicotine patch). Nicotine nasal spray demonstrates a similar
pharmacokinetic proﬁle to smoking (Zevin et al., 1998), and consistent
with our ﬁndings, there is some evidence that CPT-IP performance of
smokers with schizophrenia is unaffected by nicotine nasal spray
(Sherr et al., 2002). Furthermore, Levin et al. (1996) and Sacco et al.
(2005) both used Conner’s CPT. In Conner’s CPT, selective attention
and response inhibition are more strongly emphasised (Dépatie et al.,
2002), whereas CPT-IP (used in the current study) is a more sensitive
assessment of sustained attention and working memory processes
(Dépatie et al., 2002; Michie et al., 2000). One potential implication is
that, in schizophrenia, the neural networks mediating selective atten-
tion and response inhibition (i.e. Conner’s CPT) may demonstrate a dif-
ferential response to nicotine, relative to sustained attention and
working memory (i.e. CPT-IP). Comparing the effect of nicotine across
different CPT task versions in a single studymay help to clarify apparent
discrepancies in the literature.
Contrary to expectation, PPI in smokers with schizophrenia was un-
affected by smoking status. In light of existing evidence (e.g. Adler et al.,
1993; George et al., 2006; Olincy et al., 2006; Woznica et al., 2009) it
would be premature to interpret the current ﬁndings as evidence for
an absence of effect. The observed discrepancy between the current
ﬁndings and existing evidence may result from differences in the
proximity between smoking and assessment (due to counterbalancing
in the current study) and the use of left, relative to right eye EMG. For
example, Cadenhead et al. (2000) demonstrated that, as a group,
smokers exhibited higher PPI for right but not left eye EMG (CadenheadFig. 5. Scattergrama of difference scores for CPT-IP hits (block two) in relation to self-
reported ‘cognitive’ smoking motivation scores in non-psychiatric smokers. aGenerated
from two tailed spearman rank correlate.et al., 2000). The relative effect of nicotine on right vs. left eye EMG
represents an interesting area for future research. Utilisation of bilateral
recording procedures may help to more clearly elucidate whether
smoking related effects in schizophrenia demonstrate evidence of
hemispheric asymmetry.
In summary, we predicted that smoking related change on three pu-
tative endophenotypic markers would be strongest for smokers with
schizophrenia. This hypothesis was supported by evidence from a
computerised version of the VSWM task, but not CPT-IP or PPI. Impor-
tantly, change in VSWM function was speciﬁc to the schizophrenia
group and occurred irrespective of the factors that may have contribut-
ed to null effects on CPT-IP (e.g. nicotine dose) and PPI (e.g. temporal
proximity to nicotine). Evidently, VSWM function may be especially
sensitive to smoking related performance change in schizophrenia.
Informed by the cognitive self-medication hypothesis, we predicted
that smokers with schizophrenia would offer a higher level endorse-
ment of cognitive motivators for smoking and furthermore, that
smokers who reported stronger cognitive motivations for smoking
would also demonstrate a stronger impact of nicotine on cognitive func-
tioning. Our data suggest that, on themeasures used here, there is no in-
ﬂation of cognitive motives in schizophrenia relative to non-psychiatric
smokers. According to the Primary Addiction Hypothesis (Chambers
et al., 2001), addiction is conceived to be a primary symptom of the
schizophrenia syndrome, due to fundamental commonalities in the
neurobiology of schizophrenia and addiction (Chambers et al., 2001).
Therefore, our self-report data could be interpreted as evidence for
smoking in schizophrenia as a biologically driven process (addiction
vulnerability) that is independent from subjective awareness.
However, we did ﬁnd an interesting relationship between cognitive
motivators and smoking related change in the sustained attention per-
formance of controls. It is noteworthy that the cognitive task with
which self-reported cognitive motives did correlate could be argued to
be the most general and most easily deﬁnable in lay terms — that is,
sustained attention. This ﬁnding could be interpreted as having dual im-
plications: that if we wish to assess correlations between motivation
and cognition we require tasks that measure general abilities that map
well to lay-description of cognitive effects; and that if we wish to better
understand the pathways by which nicotine affects cognition, we may
require more speciﬁc taskswhere the contributions of various cognitive
operations can be delineated.
The current study is limited by a small sample size, meaning that we
were restricted to within subjects comparisons on cognitive measures
and correlational analyses were underpowered. Although the reporting
of within subjects effects of nicotine versus abstinence in prior research
does not enable us to calculate power for PPI and VSWM, the effect size
derived from published ﬁndings for CPT-IP (Cohen’s dz= 0.89; Dépatie
et al., 2002) supports the expectation for relatively ‘large’ effects of nic-
otine (based on Cohen, 1988) on this task. For schizophrenia partici-
pants, post-hoc power analysis using Gpower (α = .05, two-tailed,
dependent means; Faul et al., 2007) demonstrated adequate statistical
power (.80) for detecting moderate to large effects (≥ .75) of nicotine
on CPT-IP performance.
Ifwe hadnot observed any signiﬁcant effects thenonemight reason-
ably question that the signiﬁcance of the results might be limited by
sample size. However, what we did see was a signiﬁcant effect on
VSWM in patients despite no signiﬁcant effect on CPT-IP and PPI. This
result then replicates published ﬁndings in an independent laboratory
and adds to the evidence that this measure appears particularly sensi-
tive to nicotine effects in schizophrenia. Moreover, unlike several prior
investigations (e.g. George et al., 2006; Olincy et al., 2006; Sacco et al.,
2005) we did not experimentally manipulate the nicotinic agonist/an-
tagonist administration. It was therefore possible to counterbalance
the smoking and abstinent appointment and thereby reduce the contri-
bution of any practice or order effects. This design distinguishes the cur-
rent study from prior research in the area (e.g. Levin et al., 1996; Sacco
et al., 2005; George et al., 2006; Postma et al., 2006) and should be
32 A.K. Beck et al. / Schizophrenia Research: Cognition 2 (2015) 26–32considered in interpreting differences in smoking related effects in the
current study, relative to prior research.
It is alsoworth noting that the abstinent criterion adopted in the cur-
rent study (b12 ppm) is consistent with some (e.g. Kumari et al., 1996;
Kumari and Gray, 1999), but higher than others (e.g. Sacco et al., 2005;
Smith et al., 2002). Given that the mean CO level for both participant
groups during the abstinent appointment (control = 8.78; schizophre-
nia = 8.75) is comparable to studies adopting the more stringent crite-
rion (e.g. Sacco et al., 2005), surreptitious smoking is unlikely to have
contributed to our ﬁndings. However, future research should consider
employing more deﬁnitive methods for verifying abstinence (e.g. plas-
ma nicotine levels).
In summary, task choice in this study was based on those for which
existing data supported nicotine effects in schizophrenia (see Sacco
et al., 2004). Whether these are the most sensitive indices and indeed
the speciﬁc components of task performance facilitated by nicotine
has yet to be determined. Developing sensitive indices of nicotine-
induced cognitive enhancement is an important precursor to attempts
to link changes in performance on these tasks to self-report motives,
as is the challenge of developing more intuitive descriptions of how
ability changes might manifest in everyday life. Findings from the cur-
rent study highlight several methodological considerations for this
type of research and promising avenues for future study. Improved un-
derstanding of the subjective, neurophysiological and neurocognitive
effects of nicotine represents an important step for developing im-
proved smoking cessation strategies.
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